Nuclear Medicine Therapy

  Prostate Cancer , according to the World Cancer Research Fund, is not only one of the most common malignancy in men, but also one of the most commonly occurring cancer overall. The incidence of prostate cancer increases proportionally with age, especially in men above 60 years of age. For advanced prostate cancer patients or metastatic castration-resistant prostate cancer (mCRPC) patients, conventional treatment modalities, such as surgery, chemotherapy etc. might not prove to be highly effective in terms of controlling the spread of the cancer. This is where Nuclear Medicine and Molecular Imaging are playing an important part in the management of cancer and that too in a personalized manner. Several nuclear medicine clinics around world have confirmed that there is now a new hope for metastatic castrate-resistant prostate cancer (mCRPC) patients –  Targeted Alpha Therapy of Alpha PSMA   Therapy using radiolabeled PSMA inhibitors or alpha-emitting radioisotopes, suc...

  In the past one year, the Nuclear Oncology Experts team at the Department of Nuclear Medicine at Fortis Memorial Research Institute has treated 30 new patients of Castrate Resistant Prostate Cancer (CRPC) with  Ac225 PSMA Therapy  (Targeted Alpha Therapy). And the results are similar to the results being achieved by most good Nuclear Medicine Centres across the world – 75-80% of the patients have shown evidence of a significant Radiological and Biochemical Response with prolonged duration of response. ADVERSE EFFECTS: The Ac225 PSMA Therapy is extremely well tolerated with minimal adverse effects that usually do not require any active management. The adverse effects usually experienced are fatigue in the immediate post-therapy, a transient mild drop in blood counts approximately three-weeks post-therapy and dry mouth. SOURCING OF Ac 225: The Ac225 used at the center is a highly purified form with no added carriers. It is approved by the European Medicines Associ...